Osteogenesis Imperfecta Treatment Market Expected to Grow at 4.4% CAGR Through 2029: Industry Forecast

 Get 20% Off Market Intelligence Reports With Code ONLINE20 — Track Global Tariffs, Economic Shifts, and Sector Transformations

 

 What Is the Osteogenesis Imperfecta Treatment Market Growth Potential Across Different Regions?
 The osteogenesis imperfecta treatment market size has grown steadily in recent years. It will grow from $0.89 billion in 2024 to $0.93 billion in 2025 at a compound annual growth rate (CAGR) of 4.6%. The growth in the historic period can be attributed to an increasing number of clinical trials for oi-specific drugs, rising healthcare expenditure in rare disease management, growing focus on personalized and regenerative medicine, increasing availability of genetic counseling and screening, and rising collaborations between pharma and biotech companies.
 
 The osteogenesis imperfecta treatment market size is expected to see steady growth in the next few years. It will grow to $1.11 billion in 2029 at a compound annual growth rate (CAGR) of 4.4%. The growth in the forecast period can be attributed increasing prevalence of osteogenesis imperfecta, rising awareness and diagnosis rates of rare genetic disorders, growing demand for effective bone health therapies, rising research funding for rare disease treatments, and growing development of monoclonal antibody therapies. Major trends in the forecast period include advancements in monoclonal antibody technology, technological advancements in 3d bone imaging and diagnostics, development of novel drug delivery systems, advancements in stem cell therapy and regenerative treatments, and integration of telemedicine platforms for remote patient management.
 
 Claim your free report sample now:
 https://www.thebusinessresearchcompany.com/sample.aspx?id=24639&type=smp
  
 What Are the Top Drivers and Growth Contributors in the Osteogenesis Imperfecta Treatment Market?
 The increasing prevalence of osteogenesis imperfecta is expected to propel the growth of the osteogenesis imperfecta treatment market going forward. Osteogenesis imperfecta is a genetic disorder characterized by fragile bones that break easily due to defective or insufficient type I collagen. The rise in osteogenesis imperfecta cases is mainly due to improved genetic testing and diagnostic awareness, leading to better detection of previously overlooked cases. Osteogenesis imperfecta treatment helps by strengthening bones, reducing fracture risk, managing symptoms, and improving mobility and quality of life. For instance, in June 2022, according to the Parliament of the United Kingdom, a UK-based governing body, osteogenesis imperfecta affected around 5,000 people in the UK. Therefore, the increasing prevalence of osteogenesis imperfecta is driving the growth of the osteogenesis imperfecta treatment market.
 
 What Are the Major Product/Service Segments in the Osteogenesis Imperfecta Treatment Market?
 The osteogenesis imperfecta treatment market covered in this report is segmented — 
 
 1) By Treatment Type: Medication, Surgery, Physical Therapy, Lifestyle Modifications
 2) By Drug Class: Teriparatide, Denosumab, Other Drug Classes
 3) By Route Of Administration: Subcutaneous, Intravenous, Oral, Other Routes Of Administration
 4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
 5) By End-User: Hospitals, Homecare, Specialty Clinics, Other End Users
 
 Subsegments:
 1) By Medication: Bisphosphonates, Teriparatide, Hormone Replacement Therapy, Pain Relievers, Calcium And Vitamin D Supplements
 2) By Surgery: Rodding Surgery, Spinal Fusion Surgery, Fracture Repair Surgery, Joint Replacement Surgery
 3) By Physical Therapy: Strength Training, Range Of Motion Exercises, Aquatic Therapy, Gait Training, Assistive Device Training
 4) By Lifestyle Modifications: Nutritional Counseling, Fall Prevention Strategies, Home Environment Modification, Activity Modification, Patient Education And Support Programs
 
 Which Trends Are Most Likely to Influence Osteogenesis Imperfecta Treatment Market Growth in the Next Decade?
 Major companies operating in the osteogenesis imperfecta treatment market are focusing on advanced therapeutics such as sclerostin inhibition therapy to accelerate bone formation and reduce fracture risk in patients with osteogenesis imperfecta (OI). Sclerostin inhibition therapy involves the use of monoclonal antibodies to block sclerostin, a protein that restricts bone growth, thereby promoting increased bone mineral density and strength. For instance, in October 2024, Ultragenyx Pharmaceutical Inc., a US-based biopharmaceutical company, received Breakthrough Therapy Designation from the FDA for its investigational therapy setrusumab (UX143). Setrusumab is a fully human monoclonal antibody designed to inhibit sclerostin, which in turn stimulates new bone formation and enhances bone strength, aiming to reduce fracture risk in patients with OI Types I, III, and IV aged two years and older.
 
 Who Are the Industry Leaders in the Osteogenesis Imperfecta Treatment Market?
 Major companies operating in the osteogenesis imperfecta treatment market are Merck & Co. Inc., Sanofi S.A., Bristol-Myers Squibb Company, Novartis AG, Amgen Inc., Teva Pharmaceutical Industries Ltd, Regeneron Pharmaceuticals Inc., Fresenius Kabi AG, Sun Pharmaceutical Industries Ltd., Apotex Inc., Aurobindo Pharma, Dr. Reddy’s Laboratories Ltd., Cipla Ltd., BioMarin Pharmaceutical Inc., Stada Arzneimittel AG, Alkem Laboratories Ltd., Ultragenyx Pharmaceutical Inc., OrthoPediatrics Corp., Ascendis Pharma A/S, Pfenex Inc., Mereo BioPharma Group PLC, BioSenic SA. 
 
 Get the full osteogenesis imperfecta treatment market report here:
 https://www.thebusinessresearchcompany.com/report/osteogenesis-imperfecta-treatment-global-market-report
 
 Which Region Is Expected to Lead the Osteogenesis Imperfecta Treatment Market by 2029?
 North America was the largest region in the osteogenesis imperfecta treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the osteogenesis imperfecta treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
 
 Contact Us:
 
 The Business Research Company 
 
 https://thebusinessresearchcompany.com/ 
 
 Americas +1 310–496–7795
 Asia +44 7882 955267 & +91 8897263534
 Europe +44 7882 955267 
 
 Email: info@tbrc.info 
 
 
 Follow Us On:
 
 LinkedIn: https://in.linkedin.com/company/the-business-research-company